论文部分内容阅读
目的:评价美沙拉嗪与肠道益生菌联用对溃疡性结肠炎(UC)治疗的效果。方法:收集我院75例UC患者临床资料,随机分成2组,对照组40例患者单纯服用美沙拉嗪治疗,观察组35例患者予以美沙拉嗪+双歧三联活菌治疗,分析两组治疗效果。结果:观察组患者总疗效91.43%,显著高于对照组75.0%;观察组经治疗后其症状总积分(2.46±0.74)分,明显低于对照组(4.13±0.69)分;随访6个月,观察组复发率8.57%,显著低于对照组27.50%。结论:与单一用药相比,美沙拉嗪联合肠道益生菌治疗UC的疗效更佳,能够有效缓解临床症状,降低疾病复发率。
AIM: To evaluate the efficacy of mesalazine and enteric probiotics in the treatment of ulcerative colitis (UC). Methods: The clinical data of 75 patients with UC in our hospital were collected and randomly divided into 2 groups. 40 patients in the control group were treated with mesalazine alone. 35 patients in the observation group were treated with mesalazine + effect. Results: The total effective rate in observation group was 91.43%, which was significantly higher than that in control group (75.0%). The total score of symptom in observation group (2.46 ± 0.74) after treatment was significantly lower than that in control group (4.13 ± 0.69) , The recurrence rate of the observation group was 8.57%, which was significantly lower than that of the control group (27.50%). Conclusion: Compared with single drug, mesalazine combined with intestinal probiotics treatment of UC better, can effectively alleviate the clinical symptoms and reduce the recurrence rate.